Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice

Endocrinology

Volumn 153, Issue 3, 2012, Pages 1387-1396

  Nam, D H ^a   Lee, M H ^a   Kim, J E ^a   Song, H K ^a   Kang, Y S ^a   Lee, J E ^b   Kim, H W ^b   Cha, J J ^a   Hyun, Y Y ^a   Kim, S H ^a   Han, S Y ^c   Han, K H ^c   Han, J Y ^d   Cha, Dae Ryong ^a  

^a Korea University   (South Korea)

^b Wonkwang University   (South Korea)

^c Inje University   (South Korea)

^d Inha University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; ADIPONECTIN; ALBUMIN; CANNABINOID 1 RECEPTOR; COLLAGEN; LIPID HYDROPEROXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RIMONABANT; SMALL INTERFERING RNA;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG EFFECT; FATTY LIVER; HEART FUNCTION; INSULIN RESISTANCE; JUXTAGLOMERULAR CELL; KIDNEY HYPERTROPHY; LIPID METABOLISM; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; URINARY EXCRETION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION; GLUCOSE; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; MALE; MICE; MICE, INBRED C57BL; PIPERIDINES; PODOCYTES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84863116720     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1423     Document Type: Article

References (40)

1. Stumvoll M, Goldstein BJ, van Haeften TW 2008 Type 2 diabetes: pathogenesis and treatment. Lancet 371:2153-2156 (Pubitemid 351885026)
2. Zimmet P, Alberti KG, Shaw J 2001 Global and societal implications of the diabetes epidemic. Nature 414:782-787 (Pubitemid 34000780)
3. Pacher P, Bátkai S, Kunos G 2006 The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462 (Pubitemid 44394908)
4. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, Harvey-White J, Mackie K, Offertáler L, Wang L, Kunos G 2005 Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298-1305 (Pubitemid 40629049)
5. Jourdan T, Djaouti L, Demizieux L, Gresti J, Vergès B, Degrace P 2010 CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 59:926-934
6. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R 2006 The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27:73-100 (Pubitemid 43228239)
7. Bermúdez-Silva FJ, Suárez J, Baixeras E, Cobo N, Bautista D, Cuesta-Muñoz AL, Fuentes E, Juan-Pico P, Castro MJ, Milman G, Mechoulam R, Nadal A, Rodríguez de Fonseca F 2008 Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 51:476-487
8. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U 2003 The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431 (Pubitemid 38063771)
9. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, Bátkai S, Marsicano G, Lutz B, Buettner C, Kunos G 2008 Hepatic CB(1) receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118:3160-3169
10. Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschöp J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschöp MH 2008 Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 57:2977-2991
11. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA 2003 Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology 167:103-111 (Pubitemid 36535298)
12. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrié P 2003 The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63:908-914 (Pubitemid 36368998)
13. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrié P 2004 CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28:640-648 (Pubitemid 38491158)
14. Janiak P, Poirier B, Bidouard JP, Cadrouvele C, Pierre F, Gouraud L, Barbosa I, Dedio J, Maffrand JP, Le Fur G, O'Connor S, Herbert JM 2007 Blockade of cannabinoid CB1 receptor improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int 72:1345-1357 (Pubitemid 350126778)
15. Barutta F, Corbelli A, Mastrocola R, Gambino R, Di Marzo V, Pinach S, Rastaldi MP, Perin PC, Gruden G 2010 Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 59:1046-1054
16. Bligh EG, Dyer WJ 1959 A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911-917
17. Kang YS, Lee MH, Song HK, Ko GJ, Kwon OS, Lim TK, Kim SH, Han SY, Han KH, Lee JE, Han JY, Kim HK, Cha DR 2010 CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int 78:883-894
18. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, Han KH, Kim HK, Kang YS, Han JY, Kim YS, Cha DR 2006 Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17:1362-1372 (Pubitemid 43673416)
19. Han SY, Kang YS, Jee YH, Han KH, Cha DR, Kang SW, Han DS, Han KH, Cha DR, Kang SW, Han DS 2006 High glucose and angiotensin II increase β1 integrin and integrin-linked kinase synthesis in cultured mouse podocytes. Cell Tissue Res 323:321-332 (Pubitemid 43100273)
20. Schaffer JE 2003 Lipotoxicity: when tissues overeat. Curr Opin Lipidol 14:281-287 (Pubitemid 36688207)
21. Francis GA, Annicotte JS, Auwerx J 2003 PPAR-α effects on the heart and other vascular tissues. Am J Physiol Heart Circ Physiol 285:H1-H9 (Pubitemid 36736408)
22. Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD,Chang YS 2007 Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 18:1227-1238 (Pubitemid 46536909)
23. Proctor G, Jiang T, Iwahashi M, Wang Z, Li J, Levi M 2006 Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 55:2502-2509 (Pubitemid 44871150)
24. Tam J, Vemuri VK, Liu J, Bátkai S, Mukhopadhyay B, Godlewski G, Osei-Hyiaman D, Ohnuma S, Ambudkar SV, Pickel J, Makriyannis A, Kunos G 2010 Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120:2953-2966
25. Chen W, Tang H, Liu H, Long L, Gong Z, Zheng J, Chi M, Xie Y, Zheng Z, Li S, Wang L 2010 Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models. Eur J Pharmacol. 637:178-185
26. Cota D, Sandoval DA, Olivieri M, Prodi E, D'Alessio DA, Woods SC, Seeley RJ, Obici S 2009 Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity 17:1641-1645
27. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, Chabbert M, Cruccioli N, Pfersdorff C, Roque C, Arnone M, Croci T, Soubrié P, Oury-Donat F, Maffrand JP, Scatton B, Lacheretz F, Le Fur G, Herbert JM, Bensaid M 2007 Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46:122-129 (Pubitemid 47171928)
28. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF 2006 RIO-diabetes study group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368:1660-1672 (Pubitemid 46048528)
29. Hollander PA, Amod A, Litwak LE, Chaudhari U 2010 ARPEGGIO study group. Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial. Diabetes Care 33: 605-607
30. Dugail I, Le Lay S, Varret M, Le Liepvre X, Dagher G, Ferré P 2003 New insights into how adipocytes sense their triglyceride stores. Is cholesterol a signal? Horm Metab Res 35:204-210 (Pubitemid 36754195)
31. Chang WJ, Rothberg KG, Kamen BA, AndersonRG1992 Lowering the cholesterol content of MA104 cells inhibits receptor-mediated transport of folate. J Cell Biol 118:63-69
32. Parpal S, Karlsson M, Thorn H, Strålfors P 2001 Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogenactivated protein j kinase control. J Biol Chem 276:9670-9678
33. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G 2003 Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52:1799-1805 (Pubitemid 36792473)
34. XuH, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H 2003 Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830 (Pubitemid 38063705)
35. Mårin P, Andersson B, Ottosson M, Olbe L, Chowdhury B, Kvist H, Holm G, Sjöström L, Björntorp P 1992 The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism 41: 1242-1248
36. Jiang T, Liebman SE, Lucia MS, Li J, Levi M 2005 Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease. Kidney Int 68:2608-2620 (Pubitemid 43251007)
37. Jun H, Song Z, Chen W, Zanhua R, Yonghong S, Shuxia L, Huijun D, Zanhua R, Yonghong S, Shuxia L, Huijun D 2009 In vivo and in vitro effects of SREBP-1 on diabetic renal tubular lipid accumulation and RNAi-mediated gene silencing study. Histochem Cell Biol 131: 327-345
38. Wang Z, Jiang T, Li J, Proctor G, McManaman JL, Lucia S, Chua S, Levi M 2005 Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 54:2328-2335 (Pubitemid 41134259)
39. McLaughlin T, Sherman A, Tsao P, Gonzalez O, Yee G, Lamendola C, Reaven GM, Cushman SW 2007 Enhanced proportion of small adipose cells in insulin-resistant vs. insulin-sensitive obese individuals implicates impaired adipogenesis. Diabetologia 50:1707-1715 (Pubitemid 47036653)
40. McLaughlin T, Deng A, Yee G, Lamendola C, Reaven G, Tsao PS, Cushman SW, Sherman A 2010 Inflammation in subcutaneous adipose tissue: relationship to adipose cell size. Diabetologia 53:369-377